Mnemosyne Pharmaceuticals Inc.
Selective NMDA modulators for neuropsychiatric disorders
This article was originally published in Start Up
Executive Summary
Less than half of patients with major depressive disorder respond to current therapies; that’s why clinical studies showing that the anesthetic medication ketamine benefitted MDD patients within hours made headlines, despite ketamine’s serious drawbacks. Mnemosyne Pharmaceuticals Inc. has identified a highly selective oral compound that hits the same target as ketamine but with less of the effects that can lead to abuse.
You may also be interested in...
With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Patheon Tightens The Supply Chain To Transform Pharma Outsource Manufacturing
Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.
Polaris Stays Disciplined For Breakthroughs: An Interview With Alan Crane
The demands of building new biotechs can take their toll, yet Alan Crane wears his 52 years and over two decades of high-risk biotech start-up investing lightly. He's built an exceptional number of companies during his tenure at Polaris, many of which have proved to be among the industry’s more successful emerging ventures.